Team members

• Head of the genomic platform: Nathalie DROIN, PhD
  (nathalie.droin@gustaveroussy.fr)
• Marie BRECKLER, Technician
• Betty LEITE, Technician
• Audrey NAIMO, Technician
• Maëla FRANCILLETTE, engineer
• Béatrice FIET, assistant manager

Collective email address: GD-UGF@gustaveroussy.fr

Equipment

• 2 Bioanalyzer 2100 (Agilent)
• 1 FragmentAnalyzer (Agilent)
• 1 S220 Ultrasonicator (Covaris)
• 1 E220 Ultrasonicator (Covaris)

• 1 Robot Bravo (Agilent)
• 1 Robot SpriWorks (Beckman)

• 2 Chromium™ Controller (10X Genomics)
• 1 Tapestri (Mission Bio)

1 NovaSeq6000 (Illumina)

• 1 MiSeq (Illumina)
• 1 MiniSeq (Illumina)
• 1 PromethION 48 (Oxford Nanopore)

Gustave Roussy's US AMMICa Genomics Platform (INSERM US23 / CNRS UMS3655) aims to characterize cancers and experimental models using innovative genomic approaches.

Imaging and Cytometry Platform

• Cytometry & Mass imaging
• Microscopy
• Clinical Transfer Imaging

Gustave Roussy Transfert team members​

• CEO
  Fabrice Barlesi
• Executive director
  Christophe Javaud 
• Business developers
  Jérôme Gaborit
  Pierre Gandille
• Patent engineer / Responsable propriété intellectuelle
  Frédérique Le Bellego
• Patent engineer
  Sacha Cataldo
• Chargée de mission Accords et licences / Responsable gestion financière
  Daphné Descarpentries

From Innovation to the Patient

In 2000, Gustave Roussy established its subsidiary devoted to development: Gustave Roussy Transfert.

Epidemiology of cancer

The epidemiology of cancer is the study of the prevalence of disease in human populations and variations in that prevalence resulting from a variety of factors including the environment, life style and genetic characteristics. The Epidemiology Unit at Gustave Roussy is within the Gustave Roussy Biostatistics and Epidemiology Department. 

The Pharmacovigilance Unit (UFPV) of the Clinical Research Division of Gustave Roussy performs real-time assessment of the safety of the investigational medicinal products used in nearly 90 clinical trials sponsored by Gustave Roussy or by other academic sponsors, in particular, from the Ile-de-France region (within the framework of GIRCI*). Constant attention is paid to monitoring the safety of investigational medicinal products with regard to potential side effects in patients. This is called pharmacovigilance for clinical trials.

Lab members

Direction:

• Director: Gianluca Severi (Inserm DR2)
• Co-directors: Alexis Elbaz (Inserm DR2) – Pascal Guenel (Inserm DR2)
• Operational manager: Pascale Gerbouin-Rérolle

Research Axis:

Publications

By October 2022, data from the E3N-E4N cohort have contributed to the publication of more than 250 scientific papers.

Here is a selection of 20 recent key papers published by the Exposome and Heredity team (post 2010):